CASP3 and endometrial cancer: Girouard et al. [12] demonstrated that Akt2 down-regulation in endometrial cancer cells sensitizes cells to cisplatin by inducing the activation of pro-apoptotic factors such as the cleavage of caspases-3, −6, −9, and PARP.